Editorial
Copyright ©The Author(s) 2016.
World J Hepatol. Jul 28, 2016; 8(21): 863-873
Published online Jul 28, 2016. doi: 10.4254/wjh.v8.i21.863
Table 2 Tgerapectic agents against hepatitis B virus currently in clinical development
Mode of actionsTargetStage of developmentRef.
Entry inhibitionsNTCPMyrcludex in phage 2[14,123]
cccDNA
Formation inhibitionsDSSPreclinical[99]
Transcription inhibitionsASOIONIS-HBVRx in phase 1[98]
Destabilization/degradationZFNPreclinical[100,101]
TALENPreclinical[102,103]
CRISPR/Cas9Preclinical[109-117]
SiRNAPgRNAARC-520 in phase 2[95]
Nucleocapsid assembly inhibitionsCapsid formationBAY4109 in phase 1[93,95]
NV1221 in phase 1[93,95]
Reverse transcription inhibitionsPolymeraseTAF in phase 3[93,94]
Cmx157 in phase 1/2[93,95]
HBsAg release inhibitionsHBsAg secretionPreclinical[109]
HBsAg secretionRep2139 in phase 1/2[110]
Immune modulatingTLR-7 agonistGS-9620 in phase 2[67,68]
HBV-specificPreclinical[84]
cIAPSPreclinical[86]